MedTrace Logo

Collection of Plasma From People Who Recovered From or Were Vaccinated to Emerging Infectious Diseases

NCT02338986 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2025-05-16

No results posted yet for this study

Summary

Background:

\- There are more emerging infectious diseases recently. Some could affect many people. Some like Severe Acute Respiratory Syndrome (SARS) or Middle East Respiratory Syndrome (MERS) are caused by new germs. Sometimes known germs suddenly infect new and large areas, like Ebola. Many of these diseases don t have good treatments available. Researchers may be able to develop a treatment by using antibodies against these infections.

Objective:

\- To collect antibodies from people with high levels of antibodies to the diseases being studied.

Eligibility:

\- Ages 18-70 years old who weigh at least 110 pounds. They may have been infected with or vaccinated for one of the new infections researchers are studying.

Design:

* Participants will be screened with medical history and blood tests. Researchers will determine if the participant can have apheresis.
* Participants will have apheresis. First, they will be interviewed. Then, a needle will be placed in a vein. Blood will be drawn, and a machine will separate the blood cells from the antibodies and protein. The blood cells will then be returned to the participant through another vein. It takes about 60 minutes for the actual collection.
* Participants will be asked to have the procedure at least 3 times. They can participate in up to 20 sessions total as part of this study. There must be at least 7 days between sessions.

Conditions

  • Communicable Diseases
  • Communicable Diseases, Emerging
  • Emerging Infectious Diseases
  • Infection

Interventions

DRUG

Plasma

Plasma

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Richard T Davey, M.D. · National Institute of Allergy and Infectious Diseases (NIAID)

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-04
Primary Completion
2025-05-15
Completion
2025-05-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02338986 on ClinicalTrials.gov